|
|
|
| home > ebr > Autumn 2013 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
Regulatory
Long-Term Data Storage
The rapid data growth in biopharmaceutical and life sciences companies is far outweighing their IT budgets. Jim Cook at Arkivum suggests some likely strategies to address this issue.
|
|
|
|
Strategy and Finance
Rising Up: Part 1
Mounting healthcare costs in the US are prompting a change from free-pricing to value-based pricing of pharmaceuticals, as Graham Scholefield and Markus Thunecke at Catenion demonstrate. |
|
|
|
|
Data Analysis
New Generation
The industry has taken a bold step in regards to allergen testing. A sector that once relied heavily on animal testing is now using data analysis tools to move away from this controversial area, says Carl-Johan Ivarsson at Qlucore. |
|
|
|
Research and Development
Collaboration Schemes
The diminishing number of new drugs reaching the market, combined with decreasing R&D productivity and a low return on investment, makes Big Pharma an uncertain environment. Nicolas Carboni at SATT Conectus Alsace highlights a key factor in steering the industry back on track. |
|
|
|
Business Development
Global Challenges
Chris McCourt at TransPerfect reviews the approaches that the biopharma industry can use to tackle worldwide growth challenges. |
|
|
Medicinal Regulations
Cellular Therapy
Julian R De Havilland, Anne Black and Anne Dickinson at Newcastle University reveal why advanced therapy medicinal products are rapidly coming to the forefront of commercialisation.
|
|
|
|
|
|
Antibody Drug Conjugates
Characterisation Challenges
There are two classes of compounds that arise when considering anticancer medications – monoclonal antibodies and potent, cytotoxic drugs. Ashleigh Wake at Intertek takes a look at each. |
|
|
|
Therapy Engineering
Self Healing
Autologous and allogeneic cells can assist the body in restoring tissue and treating diseases, explain Eytan Abraham, Ayelet Chajut and Lena Pinzur at Pluristem Therapeutics. |
|
|
|
|
Falsified Drugs
Counterfeit Chain: A Global but Local Effort
Fake medicines not only cost the industry millions in revenue, they are also dangerous for patients’ health. Inass Hassan at Deallus Consulting suggests how government bodies, regulators and Big Pharma can tackle this issue together. |
|
|
|
|
Analytical Development
Ensuring Success
Riet Dams and Chris Bland at Aptuit discuss how a controlled approach for validation methods indicating high-performance liquid chromatography in substances can allow for more effective results. |
|
|
Market Authorisation
Gaining Approval
Thilo Kaltenbach at Arthur D. Little Healthcare assesses how Big Pharma can implement specific policies to ensure that a new drug is successfully authorised.
|
|
|
|
|
Industry Interview
Staying Focused
Jerry Boxall, Managing Director of ACM Global Central Laboratory, outlines his business philosophy, motivation and what he thinks the industry needs to focus on at the moment. |
|
|
Industry Interview
Moving Forward
Bill Newell, Chief Executive Officer of Sutro Biopharma, discusses which novel classes of therapeutics we should keep our eyes on, as well as revealing the secrets of his success.
|
|
|
|
|
Peptides
Best in Class
Archana Gangakhedkar at American Peptide Company illustrates how an emerging branch of peptide molecules with favourable properties could target diseases. |
|
|
Bioimaging
Double Act
When trying to understand dosage form performance in compounds, gamma scintigraphy and pharmacoscintigraphy are opening the door for larger formulation studies. Fiona McInnes, Lee Ann Hodges and Howard Stevens at Bio-Images Group explain why.
|
|
|
|
Biopharma Developments
Ultra Culture
The measurement of viscosity during the early development of pharmaceuticals is an essential stage of the drug process. Lisa Newey-Keane at Malvern Instruments considers the advantages of ultraviolet area imaging with microcapillary viscometry.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
DuPont Achieves Non-GMO Certification for SeaGel®, Reinforces Commitment to Sustainable, Quality Ingredients
More info >> |
|
 |
White Papers |
 |
|
Mauritius Island – An Emerging Centre for R&D in Biotechnology and the Life Sciences
CIDP (Centre International de Développement Pharmaceutique)
Mauritius, the tropical island situated in the Indian Ocean and known
worldwide for its beautiful beaches, is also internationally recognised
for its rule of law, and political and social stability. Over the past
few years, the economy has been successfully transitioned from a
monocrop to a diversified innovation-driven and knowledge-based economy,
resting on agribusiness, export-oriented manufacturing, tourism,
financial services, property development and real estate, ICT-BPO, the
seafood industry, a free port, logistics and a nascent ocean economy.
Emerging sectors such as healthcare and life sciences are presenting
some niche areas for the taking, and the enabling environment is being
put in place to make it happen - especially in the light of sustained
growth within pharmaceutical, medical device, and clinical research.
Important
international players are already in operation locally as the country
has established the appropriate legal and regulatory frameworks based on
international norms, for the development of a strong biomedical
research sector.
More info >> |
|
 |
Industry Events |
 |
12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
8-11 February 2021, Vienna, Austria
In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >> |
|
|
